Kiniksa reports ~$182M year-end cash sufficient into 2024; mavrilimumab Phase 3 fails; pipeline updates

Kiniksa Pharmaceuticals International, plc

Preliminary year-end 2021 cash, cash equivalents and short-term investments of ~$182M (unaudited), expected to fund operations into 2024.
Mavrilimumab Phase 3 in COVID-19 ARDS did not meet primary endpoint; company evaluating next steps.
Full-year 2022 ARCALYST net revenue guidance to be provided with Q4 and full-year 2021 financial results.
Vixarelimab Phase 2b data in prurigo nodularis expected in second half of 2022.
KPL-404 Phase 2 trial in rheumatoid arthritis now enrolling and dosing patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.